https://doi.org/10.4081/ejh.2023.3655
Expression and clinical significance of HER2/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer
Submitted: 27 January 2023
Accepted: 31 July 2023
Published: 10 August 2023
Accepted: 31 July 2023
Abstract Views: 410
PDF: 365
HTML: 5
HTML: 5
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
This study aimed at exploring the expression and clinical significance of aromatase P450, adhesion molecule CD24 and HER2/neu in endometrial cancer. The expression of aromatase P450, adhesion molecule CD24 and HER2/neu was detected by immunohistochemistry in 15 cases of endometrial hyperplasia group, 50 cases of endometrial adenocarcinoma and 3 cases of uterine papillary adenocarcinoma, with 15 cases of normal endometrium as control group. We detected no expression of aromatase P450, adhesion molecule CD24 or HER2/neu in control group. Aromatase P450 positive expression rate was 66.7% in endometrial hyperplasia group and 70.3% in endometrial carcinoma group, without significant difference (p>0.05). There was no significant difference (p>0.05) in the positive expression rate of aromatase P450 between different myometrial invasion groups of endometrial adenocarcinomas. CD24 positive expression rate was 40.0% in endometrial hyperplasia group and 79.6% in endometrial carcinoma group, with significant difference (p<0.05). HER2/neu positive expression rate was 26.7% in the endometrial hyperplasia group and 57% in endometrial carcinoma group, with significant difference (p<0.05). In conclusion, aromatase P450 may be one factor associated with endometrial cancer cell proliferation, while CD24 and HER2/neu may be important factors associated with the invasion and metastasis of endometrial cancer.
Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center 2022;2:1-9.
DOI: https://doi.org/10.1016/j.jncc.2022.02.002
Yang X, Ma K, Chen R, Zhang N, Meng Y, Wen J, et al. Immunocytochemical examination of PTEN and Ki-67 for endometrial carcinoma using thin-layer endometrial preparations. Biocell 2021;45:923-32.
DOI: https://doi.org/10.32604/biocell.2021.013625
Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem 2002;80:203-12.
DOI: https://doi.org/10.1016/S0960-0760(01)00187-X
Brodie AMH, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, et al. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem 2001;79:41-7.
DOI: https://doi.org/10.1016/S0960-0760(01)00131-5
Kaipparettu BA, Malik S, Konduri SD, Liu W, Rokavec M, Van Der Kuip H, et al. Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer 2008;123:66-72.
DOI: https://doi.org/10.1002/ijc.23480
Altevogt P, Sammar M, Hüser L, Kristiansen G. Novel insights into the function of CD24: A driving force in cancer. Int J Cancer 2021;148:546-59.
DOI: https://doi.org/10.1002/ijc.33249
Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19:56-62.
DOI: https://doi.org/10.1097/GCO.0b013e328012980a
Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014;138:343-50.
DOI: https://doi.org/10.5858/arpa.2012-0416-RA
Gardella B, Dominoni M, Bogliolo S, Cassani C, Carletti GV, De Silvestri A, et al. Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women? BMC Palliat Care 2021;20:28.
DOI: https://doi.org/10.1186/s12904-021-00719-0
Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-9.
DOI: https://doi.org/10.1007/s00432-003-0427-9
Carreau S, Bourguiba S, Lambard S, Galeraud-Denis I, Genissel C, Levallet J. Reproductive system: aromatase and estrogens. Mol Cell Endocrinol 2002;193:137-43.
DOI: https://doi.org/10.1016/S0303-7207(02)00107-7
Qian B, Huang Y, Qiu Z, Ying X, Yang G, Li H, et al. Tet methylcytosine dioxygenase 2 suppresses renal cell cancer proliferation and metastasis by regulating the miR-200c-SCD axis. Biocell 2021;45:599-615.
DOI: https://doi.org/10.32604/biocell.2021.014633
Lin CY, Tsai CL, Chao A, Lee LY, Chen WC, Tang YH, et al. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression. J Mol Med (Berl) 2021;99:1125-37.
DOI: https://doi.org/10.1007/s00109-021-02079-x
Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004;95:570-5.
DOI: https://doi.org/10.1016/j.ygyno.2004.08.043
Wang X, Yue J, Kang Y, Dai Z, Ju J, Wang J, et al. Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine. Cancer Biol Med 2023;20:287-96.
DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0702
Han S, Park S, An J, Yang J-Y, Chung J-W, Kim YJ, et al. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. Sci Rep 2020;10:5270.
DOI: https://doi.org/10.1038/s41598-020-61567-1
Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, et al. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Lett 2019;461:21-30.
DOI: https://doi.org/10.1016/j.canlet.2019.06.011
Buchynska LG, Brieieva OV, Iurchenko NP. Assessment of HER-2 neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas. Exp Oncol 2019;41:138-43.
DOI: https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.12973
Afify AM, Werness BA, Mark HFL. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp Mol Pathol 1999;66:163-9.
DOI: https://doi.org/10.1006/exmp.1999.2255
Malamou-Mitsi V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, et al. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 2007;27:1157-65.
Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.
DOI: https://doi.org/10.1016/S0002-9378(12)90907-2
Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Nat Cancer Center 2022; 2:277-90.
DOI: https://doi.org/10.1016/j.jncc.2022.09.002
Ethics Approval
this study was approved by ethics board of Hebei Medical University, Shijiazhuang, China (approval No. 202871)Supporting Agencies
Key Medical Science Research Program of Hebei ProvinceHow to Cite
Guan, L., Wang, Y., Cheng, J., Zhang, J., & Kang, S. (2023). Expression and clinical significance of HER2/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer. European Journal of Histochemistry, 67(3). https://doi.org/10.4081/ejh.2023.3655
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Jiancai Ouyang, Fuhu Song, He Li, Rui Yang, Haicheng Huang, miR-126 targeting GOLPH3 inhibits the epithelial-mesenchymal transition of gastric cancer BGC-823 cells and reduces cell invasion , European Journal of Histochemistry: Vol. 64 No. 4 (2020)
- G. Lepore, S. Gadau, A. Mura, M. Zedda, V. Farina, Aromatase immunoreactivity in fetal ovine neuronal cell cultures exposed to oxidative injury , European Journal of Histochemistry: Vol. 53 No. 4 (2009)
- Manuela Monti, Mistletoe - From mythology to evidence-based medicine , European Journal of Histochemistry: Vol. 59 No. 4 (2015)
- I.C. Šoštarić-Zuckermann, K. Severin, M. Huzak, M. Hohšteter, A. Gudan Kurilj, B. Artuković, A. Džaja, Ž. Grabarević, Quantification of morphology of canine circumanal gland tumors: a fractal based study , European Journal of Histochemistry: Vol. 60 No. 2 (2016)
- M. Costanzo, F. Carton, A. Marengo, G. Berlier, B. Stella, S. Arpicco, M. Malatesta, Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery , European Journal of Histochemistry: Vol. 60 No. 2 (2016)
- Qichao Yin, Hua Xiong, Chemotherapy-induced nephrotoxicity was improved by crocin in mouse model , European Journal of Histochemistry: Vol. 66 No. 4 (2022)
- L. Pilloni, P. Bianco, E. DiFelice, S. Cabras, M.E. Castellanos, L. Atzori, C. Ferreli, P. Mulas, S. Nemolato, G. Faa, The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions , European Journal of Histochemistry: Vol. 55 No. 2 (2011)
- Letizia Ferroni, Chiara Gardin, Andrea De Pieri, Maria Sambataro, Elena Seganfreddo, Chiara Goretti, Elisabetta Iacopi, Barbara Zavan, Alberto Piaggesi, Treatment of diabetic foot ulcers with Therapeutic Magnetic Resonance (TMR®) improves the quality of granulation tissue , European Journal of Histochemistry: Vol. 61 No. 3 (2017)
- E. Tarantola, V. Bertone, G. Milanesi, E. Capelli, A. Ferrigno, D. Neri, M. Vairetti, S. Barni, I. Freitas, Dipeptidylpeptidase-ÂIV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats , European Journal of Histochemistry: Vol. 56 No. 4 (2012)
- C. Pellicciari, Histochemistry as an irreplaceable approach for investigating functional cytology and histology , European Journal of Histochemistry: Vol. 57 No. 4 (2013)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
You may also start an advanced similarity search for this article.
